Pfizer/Merck KgAA Move Fast With Bid For Bavencio/Inlyta In Kidney Cancer Market
Executive Summary
Study of PD-L1/TKI combo succeeded in an all comers population across risk groups, which could be differentiating, for a while.
You may also be interested in...
Cash-Rich Ipsen Opens Up Checkbook For 2019
2019 looks set to be a transformative year for Ipsen, with a pivotal clinical trial readout expected for combination Cabometyx in frontline kidney and liver cancer, and a series of deals promised by the company to investors looking for reassurance over long-term growth. CEO David Meek spoke to Scrip.
10 Things For Pfizer's New CEO To Worry About
Albert Bourla will face opportunities and potential pitfalls.
Bristol Touts Opdivo's Stability – And Diversity – In Strong Q2
The recently launched Opdivo/Yervoy combination already has a leading position in first-line kidney cancer in the US – with a 30% share of new patients – but has been rejected in Europe.